NY -- Standard&Poor's CreditWire 11/20/98 -- Standard&Poor's today assigned its 'A-1'-plus rating to Bristol-Myers Squibb Co.'s US$200 million Euro commercial paper program. At the same time, Standard&Poor's affirmed its triple-'A' corporate credit, senior unsecured debt, and bank loan ratings, preliminary triple-'A' shelf debt rating, and its 'A-1'-plus rating on the company's existing U.S. commercial paper program for Bristol-Myers Squibb Co. The outlook remains stable. The ratings continue to reflect Bristol-Myers' position as one of the world's largest pharmaceutical firms, the company's diverse and growing revenue base, and its solid financial position. Bristol-Myers' pharmaceutical operations, which account for about 60% of total sales, anchor a broad business portfolio. The company's best-selling product, Pravachol, a heart
